5 completed, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow rilapladib: new trials by email Literature Review of rilapladib trials Research Report on rilapladib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers Rilapladib 25 mg, Rilapladib 250 mg, Itraconazole - Alzheimer's Disease | Phase 1 | Withdrawn | GlaxoSmithKline | 2017-10-01 | 2016-12-13 | |
| A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease 250mg rilapladib, placebo - Alzheimer's Disease | Phase 2 | Completed | GlaxoSmithKline | 124 | 2011-10-01 | 2018-09-24 |
| An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks rilapladib, placebo, 18F Fluorodeoxylucose (FDG)-PET - Atherosclerosis | Phase 2 | Completed | GlaxoSmithKline | 83 | 2008-11-01 | 2016-12-01 |
| Effect Of Rilapladib (SB-659032) On Platelet Aggregation Rilapladib (SB-659032) - Healthy Subjects, Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 58 | 2006-10-01 | 2015-04-15 |
| SB-659032 Platelet Aggregation Study SB-659032, Placebo - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 26 | 2005-07-01 | 2012-12-10 |
| A Study to Assess the Effect of SB 659032 on Platelet Function SB659032 - Atherosclerosis | Phase 1 | Completed | GlaxoSmithKline | 14 | 2004-09-01 | 2012-12-17 |
Atherosclerosis (4) · Alzheimer Disease (2)
GlaxoSmithKline (6)
Australia (2) · United States (2) · Bulgaria (1) · Canada (1) · Germany (1) · Italy (1) · Norway (1) · Spain (1) · Sweden (1)